Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
12.22 USD +0.41% Intraday chart for Viridian Therapeutics, Inc. +1.83% -43.89%
Jun. 06 Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target MT
May. 16 Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM

Evolution of the average Target Price on Viridian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9470edee13cfab1254071b.tY7_XF3U2vfOQGVL7zopDSrIs1rsV_6dlwC7ApitnzM.1tzMazTnic6pEQk9oUxneHKZ-m-IHM_4w0Hwa-ma3WDN2qw-bLWyrq0kLA~ab3155cc0fefdab4f2c67dd1a96f5bae

Analyst Recommendations on Viridian Therapeutics, Inc.

Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25 MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating MT
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating MT
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating MT
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024 MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $38 From $42, Maintains Market Outperform Rating MT
B. Riley Lowers Viridian Therapeutics' PT to $29 From $46 to Reflect Dilutive Financing, Lower Peak Sales in TED; Maintains Buy Rating MT
RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier MT
Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $37 From $40, Keeps Buy Rating MT
Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating MT
Wells Fargo Adjusts Price Target on Viridian Therapeutics to $39 From $46, Maintains Overweight Rating MT
Wedbush Lifts Viridian Therapeutics' PT to $46 From $45 After Adjusting Share Count Assumptions, Keeps Outperform Rating MT
Wedbush Adjusts Viridian Therapeutics' PT to $45 From $48 After Reporting Results For Phase 1/2 Trial for Chronic Thyroid Eye Disease Treatment, Keeps Outperform Rating MT
BTIG Research Initiates Coverage on Viridian Therapeutics With Buy Rating, $46 Price Target MT
RBC Initiates Viridian Therapeutics at Outperform With Speculative Risk, Sets Price Target at $44, Sees 'Best Second-Mover Advantage' in Thyroid Eye Disease MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $44 From $46, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $40 From $45, Maintains Outperform Rating MT
Wedbush Lifts Viridian Therapeutics' Price Target to $48 From $46, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
12.22 USD
Average target price
35.6 USD
Spread / Average Target
+191.33%
High Price Target
46 USD
Spread / Highest target
+276.43%
Low Price Target
20 USD
Spread / Lowest Target
+63.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viridian Therapeutics, Inc.

Goldman Sachs
Oppenheimer
B. Riley
Wedbush
JMP Securities
RBC Capital Markets
HC Wainwright
Needham & Co.
Wells Fargo Securities
BTIG
Stifel Nicolaus
SVB Securities LLC
Credit Suisse
Evercore ISI
SVB Leerink
Ladenburg Thalmann

Ratings for Viridian Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. Consensus Viridian Therapeutics, Inc.